Guggenheim lowered the firm’s price target on Outlook Therapeutics (OTLK) to $10 from $12 and keeps a Buy rating on the shares following Outlook’s fiscal Q1 earnings release. The company remains on track to re-submit a BLA in calendar Q1 and the FDA will have to evaluate the totality of the ONS-5010 clinical package to determine whether it represents two adequate and well-controlled studies, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Positive Outlook on Outlook Therapeutics: Buy Rating Supported by Strategic Launches and Market Opportunities for Lytenava
- Outlook Therapeutics price target lowered to $3 from $30 at H.C. Wainwright
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outlook Therapeutics Reports Strong Earnings and Strategic Progress
- Outlook Therapeutics reports Q1 adjusted EPS (89c) vs. (78c) last year